Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 320

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 320
---
 giving effect to the Stock Split and the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into 3,181,815 shares of common stock upon the closing of this offering. The percentage ownership information shown in the table after this offering is based on 20,100,137 shares of common stock outstanding, after giving effect to the Stock Split and the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into 3,181,815 shares of common stock upon the closing of this offering (including 382,467 additional shares issuable upon conversion of our Series C convertible preferred stock due to anti-dilution adjustments, based on an assumed initial public offering price of $15.00 per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus) and assuming the sale of 16,666,667 shares of common stock by us in this offering and no exercise by the underwriters of their option to purchase additional shares. The table below excludes any potential purchases in this offering by the beneficial owners identified in the table below. We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, the rules include shares of common stock issuable pursuant to the exercise of stock options or warrants that are either immediately exercisable or exercisable within 60 days of June 30, 2025. These shares are deemed to be outstanding and beneficially owned by the person holding those options or warrants for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, we believe based on information provided to us, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws. 214

Except as otherwise noted below, the address for each person or entity listed in the table is c/o LB Pharmaceuticals Inc, One Pennsylvania Plaza, Suite 1025, New York, NY 10119.

|                                                                          |     | Number of    
 Shares       
 Beneficially 
 Owned        |           |     | Percentage of Shares 
 Beneficially Owned   |      |   |     |     |   |
| Name and Address of Beneficial Owner                                     |     | Before       
 Offering     |           |     | After